The emerging and rapidly growing field of molecular and genomic imaging is providing new opportunities to directly visualize the biology of living organisms. By combining our growing knowledge regarding the role of specific genes and proteins in human health and disease, with novel ways to target these entities in a manner that produces an externally detectable signal, it is becoming increasingly possible to visualize and quantify specific biological processes in a non-invasive manner. All the major imaging modalities are contributing to this new field, each with its unique mechanisms for generating contrast and trade-offs in spatial resolution, temporal resolution and sensitivity with respect to the biological process of interest. Much of the development in molecular imaging is currently being carried out in animal models of disease, but as the field matures and with the development of more individualized medicine and the molecular targeting of new therapeutics, clinical translation is inevitable and will likely forever change our approach to diagnostic imaging. This review provides an introduction to the field of molecular imaging for readers who are not experts in the biological sciences and discusses the opportunities to apply a broad range of imaging technologies to better understand the biology of human health and disease. It also provides a brief review of the imaging technology (particularly for x-ray, nuclear and optical imaging) that is being developed to support this new field.
, physiology (MRI, ultrasound, PET, SPECT) or biochemistry (PET, SPECT, MRS) that could be caused by alterations in many different proteins or genes. In molecular and genomic imaging, the goal is to image the location and expression levels of specific genes and proteins that are thought to play an important part in the molecular pathways of disease. Targeted contrast agents normally are required to isolate the signal from the gene or protein of interest.
radioactively labelled contrast agents that bind to specific proteins, particularly cell-surface receptors, have been employed for decades in cell culture, tissue slice and autoradiographic studies. These techniques have since migrated to the in vivo environment, and, with the advent of nuclear imaging modalities such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), into humans, with an early emphasis devoted to studying spatially localized neuroreceptor systems in the human brain (Wagner et al 1983 , Garnett et al 1983 .
What has changed over the last several years, acting as a catalyst for the explosive growth and popularity of molecular imaging, is the extraordinary avalanche of information regarding the specific genes and proteins involved in disease mechanisms, the sequencing of the human genome (and more recently, the mouse genome) and the advent of combinatorial chemistry and mass screening techniques that produce large numbers of candidate molecules that can interact with a particular biological target of interest. In addition, the imaging field has embraced this opportunity by discovering and developing a range of novel approaches for generating protein and gene specific contrast in an image, and through stunning improvements in the imaging technologies themselves, particularly at the level of in vivo small-animal imaging. A further catalyst has been the erosion of traditional boundaries that separated physicists, engineers, mathematicians, computer scientists, chemists, cell and molecular biologists and physicians (no emphasis is intended in the order these are listed!) and the establishment, at many leading institutions, of interdisciplinary programmes where the imaging sciences and biology are seamlessly integrated.
A highly simplified schematic overview of how molecular and genomic imaging relates to modern biology and conventional diagnostic imaging is presented in figure 1 . The goal of molecular imaging as defined in this paper is to image specific proteins, genes or the biochemical and molecular pathways they are involved in, within intact living subjects. The ultimate goal is to know where specific proteins or genes are expressed in the body, the level at which they are expressed and how that distribution and level changes over time or following an intervention. There are several excellent review articles that cover the field of molecular imaging from different perspectives, and these are recommended to the interested reader (Weissleder and Mahmood 2001 , Weissleder 2002 , Gillies 2002 , Blasberg 2002a ).
Defining targets: genomics and proteomics
A critical step in utilizing molecular and genomic imaging approaches is to define the gene or protein (generally known as the 'target') that is to be imaged. This requires that something be known about the molecular mechanisms of the disease of interest, and the decision is generally based on a large body of careful and detailed work in the biological sciences to dissect out the molecular pathways involved.
Increasingly, high-throughput screening techniques are being used to find genes or proteins that are expressed at abnormally high or low levels in a particular disease. In functional genomics (Venter et al 2003 , Weber 2002 , Brown and Botstein 1999 , a range of technologies including DNA microarrays, laser capture microdissection and quantitative polymerase chain reaction (PCR) are being used to identify genes that may play a direct role in the initiation or progression of a disease. In the field of proteomics (Martin and Nelson 2001 , Phizicky et al 2003 , Yarmush and Jayaraman 2002 , techniques such as 2D gel electrophoresis and mass spectrometry are being used to separate and identify proteins. Protein function and proteinprotein interactions can be probed using a variety of assays and can in some cases also be predicted using computational approaches. Protein structures, which also can give clues regarding protein function and interactions, can be identified using x-ray crystallography and cryo-electron microscopy. New high-throughput protein-screening techniques based on microfabrication and microfluidic technologies are under development in a number of laboratories and promise to dramatically increase the speed at which proteins can be identified and their structure and function elucidated.
It is appealing, but generally misleading, to think of disease as being caused by a mutation in one single gene or a deficiency in its associated protein product. It is true that there are examples of diseases that are predominantly linked to a single gene (for example cystic fibrosis, Huntington's disease and sickle cell anaemia). In these cases, the target gene or protein is readily identified. However, most human disease involves multiple genes and proteins and is a complex mixture of genetics and environmental factors, and their interaction with the body's defence and repair mechanism, the immune system. For example, in cancer, high-throughput screening methods have shown that many genes and proteins are altered. There are patterns, in that certain genes and proteins are found to be over-or underexpressed in several different types of cancers. This indicates that these genes and proteins may play a pivotal role in the disease. Others are specific to the type of cancer. Two important sets of genes in cancer are oncogenes, which are important for regulating cell growth (examples are the fos, c-myc, abl, N-ras and Her-2/neu genes), and tumour-suppressor genes which suppress growth and survival of damaged cells (examples are the p53 and Rb gene). Mutations in these genes are implicated in the initiation of many cancers, leading to uncontrolled growth in the case of inappropriate oncogene expression, and survival and proliferation of cells with damaged DNA in the case of mutations in tumour-suppressor genes (Hanahan and Weinberg 2000) . However, these same genes are important for normal cell growth and development, hence the development of cancer is inextricably entwined with the complex cascade of molecular events that govern normal cell growth, differentiation, division and death.
A further difficulty is in distinguishing cause from effect in analysing candidate genes and proteins from high-throughput analyses of a disease. Which genes or proteins are truly causative and are therefore appropriate targets for therapeutic intervention and which are merely effects, perhaps related to an immune response or an attempt to compensate for a biochemical inbalance caused by the disease? Lastly, disease is a dynamic process. Cancer once again is a good example. As cells move from a pre-cancerous state, to cancer, to invasive metastatic cancer, there are dynamic changes in the gene and protein expression profiles. Therefore, an appropriate target for imaging metastatic breast cancer may not be an appropriate target for visualizing pre-cancerous changes in the breast.
Clearly for molecular and genomic imaging to be useful, target selection is absolutely critical. Because currently available in vivo imaging technologies can at best visualize only a small number of distinct genes or proteins in any given study (typically 1-2), these targets must be selected carefully. This involves an understanding of the molecular basis of the disease and the ability to select genes or proteins that are involved at critical points in the molecular pathway of the disease and would therefore be informative to image. The number and density of target mRNA or protein molecules must also be carefully considered, to ensure there will be sufficient signal to image. For example, numbers of mRNA molecules per cell for an individual gene range from just a few, up to as many as 10 5 in some highly over-expressed genes found in cancer. The number of protein molecules can be as high as 10 6 . In many cases, some form of signal amplification (discussed below) may be needed to render the target visible. As considerable time and effort usually is expended to develop a contrast agent that is specific to the target of interest, careful selection is key to maximizing the utility and efficiency of in vivo imaging approaches.
Target selection is a common step in developing therapeutic drugs as well as imaging contrast agents. Therefore, targets that are identified as being a critical component of the disease process are both good candidates for drug development, and for molecular imaging. Furthermore, if targets that are therapeutically relevant can also be imaged, diagnosis and therapy can ultimately work hand in hand. Imaging can establish the presence or absence of the target of interest, and can then also directly visualize the effect of a drug on that protein or gene target.
A combination of high throughput genomics and proteomics approaches, with careful and detailed dissection of the molecular pathways of disease, is leading to an explosion in the number of possible therapeutic targets that are under investigation in the pharmaceutical industry. It is estimated that currently available drugs target about 500 specific molecular targets, mostly cell-surface receptors and enzymes. It is anticipated that there are in excess of 5000-10 000 molecular targets that could be evaluated for the development of potential diagnostic or therapeutic agents (Weissleder and Mahmood 2001) . Molecular and genomic imaging is poised to play a major role in characterizing, validating and ultimately exploiting these targets in the clinic.
Targeted contrast agents and contrast mechanisms
Once a target is chosen, the next step is to develop techniques to image that target in a living subject. In virtually all cases, this involves the administration of an exogenous contrast agent with physical or chemical properties that render the agent visible when placed inside an imaging system. Common approaches are to develop targeted compounds that are labelled with a fluorescent molecule , a radioactive atom (Klimas 2002, Sharma and Piwnica-Worms 2002) , or paramagnetic ions (Aime et al 2002) , or alternatively to use small particles (e.g., microbubbles, liposomes, nanoparticles and quantum dots) that are paramagnetic, fluorescent (Chan et al 2002) , radioactive (Boerman et al 2000) or that produce strong ultrasound echoes Wickline 2001, Dayton and and that are covalently linked with targeting molecules. Contrast agents therefore come in many different sizes, depending on their application and the modality with which they are to be imaged. Table 1 shows the major classes of contrast agents in relation to their molecular size. All of these types of molecules and particles are currently being developed and exploited as molecular imaging contrast agents.
Contrast agent development also has many similarities to pharmaceutical development. A drug has to distribute throughout the body, find the target and interact with the target to modify its biologic action in some specific manner. An imaging contrast agent must also find the target, wherever it may be in the body, and must in some way interact with that target such that the contrast agent accumulates at the site of the target, or is 'switched on' by an interaction with the target. The pharmaceutical industry uses high-throughput combinatorial chemistry approaches to find molecules that have high affinity for the specific target of interest, and much lower affinity for non-target tissues. These approaches allow millions of small molecules or peptides to be rapidly screened against a chosen target to identify a relatively small number of candidate molecules to be taken into the drug development pipeline. In a similar fashion, imaging scientists are increasingly making use of large combinatorial libraries of molecules and rapid screening methods in the development of molecular imaging contrast agents that are specific to the target of interest (Maclean 2002) .
One limitation of these screening methods is that they take place in vitro. For a contrast agent (or therapeutic drug for that matter) to be successful in vivo requires that some very significant additional hurdles be overcome. Most contrast agents are administered intravenously for rapid distribution throughout the body. Stability of the contrast agent in blood is therefore of paramount importance and is not always easy to achieve due to the large number of proteolytic enzymes present in plasma. A second major barrier is delivery to the target. With the exception of intravascular targets, the contrast agent must be able to get out of the bloodstream (either by passive diffusion, or by some form of active transport mechanism) and into the tissue. In the brain, the blood-brain barrier forms a formidable barrier for contrast agent delivery (Pardridge 1998) . For extracellular targets (e.g., cell-surface receptors, extracellular enzymes), delivery into the interstitial space is sufficient. For intracellular targets, the contrast agent must go one step further and get across the cell membrane and into the cell. An ideal contrast agent will therefore rapidly and uniformly distribute throughout all the cells of the body and will remain intact and unaltered as it does so.
If the contrast mechanism used to generate an image is passive (that is the contrast mechanism is not altered in any way by interacting with the target, e.g., radioactive decay), then there is a further important requirement that any contrast agent that has encountered the gene or protein target be in some way bound or trapped, and that any contrast agent that has not encountered the gene or protein target be rapidly removed from the tissue and cleared. Image contrast is achieved through simple accumulation of the contrast agent at the location of the target. Without clearance, specific and non-specific signal cannot be separated.
To illustrate the principles of contrast generation, some specific approaches that are commonly employed in molecular and genomic imaging studies will be reviewed.
Imaging of enzymes and receptors
The two most common types of targets currently exploited in molecular imaging studies are enzymes and cell-surface receptors. Figure 2 shows schematically how such a protein target could be imaged using the simple accumulation of a contrast agent. In this case the contrast agent molecules are designed to bind tightly to a cell-surface receptor protein found only on cancer cells. The contrast agent is also designed such that unbound contrast agent is cleared fairly rapidly by the body, either through the urogenitary or hepatobiliary systems. Optical.
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Figure 2.
Schematic diagram showing imaging of a cell-surface receptor found on cancer cells using a contrast agent designed to bind tightly and specifically to that receptor. At early times (left) after contrast agent administration, the agent is distributed throughout the tissues and there is no specific binding. At later times (right), the contrast agent has found and become bound to the receptor, and most of the unbound contrast agent has been cleared from the tissues and the circulation. The signal seen at this time comes predominantly from contrast agent that is specifically bound to the target receptors. There is also some signal from contrast agent that is nonspecifically bound to other proteins, and from remaining unbound contrast agent that is still in the circulation. In this figure, the 'target-to-background' ratio for the contrast agent is 4:1 (12 contrast agent molecules are bound to the targeted receptor, 3 other molecules are present but not bound to the receptor).
After the contrast agent is administered (usually by intravenous injection), it distributes rapidly throughout the body, accessing all the cells of the body. An image taken at this early time reveals little or no specific signal (figure 2 (left)). But after waiting for some time, most of the unbound contrast agent has been cleared away, and the signal comes primarily from contrast agent molecules that are specifically bound to the receptors. Therefore, the image intensity reflects the distribution and density of these receptors (figure 2 (right)). There is always some background due to contrast agent molecules that bind to other proteins in the body (no contrast agent is 100% specific), any contrast agent remaining in the circulation, routes of excretion of the contrast agent from the body and contrast agent that has been chemically modified so that it no longer recognizes the intended target. Minimizing this background is a key goal of contrast agent development. The timing of the imaging with respect to contrast agent administration depends on the type of contrast agent, and the time taken for distribution and clearance. For small molecule contrast agents, this process may only take a few minutes, while for larger biomolecules such as antibodies, it may take several days. A similar approach can be employed with enzymes. Enzymes catalyze biochemical reactions and in this case the contrast agent can be designed so that when it encounters the enzyme, it is altered in a way that results in it being trapped in the cell. One common way this can occur is if the enzyme changes the charge on the contrast agent molecule. Charged molecules are effectively retained inside the cell, whereas uncharged small molecules generally can diffuse in and out. Therefore, over time, the contrast agent will accumulate in cells that contain the target enzyme and the distribution and concentration of the enzyme can be imaged. This method is commonly used to image a class of enzymes known as kinases. These enzymes phosphorylate specific molecules that are substrates for that enzyme, and by doing so change the charge on those molecules. One advantage of imaging enzymes over receptors is that enzymes can interact with multiple contrast agent molecules (the enzyme is not altered or destroyed in the interaction) leading to an effective amplification of the signal. The binding of a contrast agent molecule to a receptor is generally a 1:1 relationship, and hence the number of contrast agent molecules accumulated per cell is limited by the number of available receptors and their rate of turnover.
Activatable contrast agents
One of the exciting recent developments in molecular imaging has been the introduction of activatable or 'smart' contrast agents. These are agents in which the contrast mechanism can be switched 'on' or 'off' when the contrast agent molecule meets a specific biologic target. Important examples of this strategy are contrast agents designed to image enzymes that are involved in the cleavage of molecules. In the simplest implementation, the contrast agent consists of a fluorescent molecule and a quenching molecule that have a linker that is designed such that it can only be cleaved by the enzyme of interest (figure 3). In the absence of the enzyme, the fluorophore and quencher are close together and the fluorophore can transfer any excitation energy to the quencher. External excitation of the fluorophore with laser light results in little or no signal. But once the contrast agent molecules encounter the target enzyme and are cleaved, the fluorophores and quencher move apart and the excited fluorophore will now produce fluorescence light. This, and similar approaches have been used to image the activity of a number of important proteolytic enzymes (Tung et al 2000 , Bremer et al 2001 , Weissleder et al 1999 .
A second class of activatable contrast agents comes from magnetic resonance imaging . One successful example used Gd 3+ , a highly paramagnetic ion, enclosed in a molecular cage to prevent exchange with water molecules in the tissue (figure 4). In this form, it is not detectable in an magnetic resonance imaging (MRI) scan. The 'lid' of this cage once again contains a linker that is recognized by a specific enzyme. Interaction with the enzyme results in a structural change or cleavage in the linker, allowing the lid of the cage to open or be removed. Water can now access the Gd 3+ ion, changing the local susceptibility and leading to a T1 signal change in the image .
In both these examples, the contrast agent is silent when it is introduced into the body and it is activated only when it encounters the target enzyme that it is designed to detect. This leads to a huge reduction in background signal from circulating and non-specifically accumulated contrast agent, potentially allowing much lower levels of the target to be detected. These approaches are unique to optical and MR imaging where the contrast is based on chemical properties that can be modulated by interaction with the target, and not on immutable physical properties that are generally the basis for contrast in nuclear imaging and CT.
Imaging gene expression-antisense oligonucleotide methods
The methods discussed so far are useful for imaging proteins. But there is also interest in being able to image the expression level of the genes that encode for these proteins. The intuitively obvious way to approach this is to develop contrast agents that will bind to the mRNA molecules produced when a gene is transcribed ( figure 5 ). This approach, known as in situ hybridization, is widely used in cell culture and tissue slice studies, where small segments of RNA that are complementary and specific to the base sequence of the mRNA of the gene of interest are tagged with a fluorescent molecule or a radionuclide. These short segments
Contrast agent hybridized to mRNA Figure 5 . Top: when a gene is expressed, the DNA corresponding to that gene is transcribed into messenger RNA (mRNA). Middle: these mRNA molecules can be targeted by creating contrast agents that contain the complementary sequence (antisense oligonucleotides) of bases. A sequence of roughly 15-20 bases is usually sufficient to give specificity for the gene of interest. Bottom: when the antisense oligonucleotide contrast agent finds the mRNA with the right sequence it will hybridize (bind) to it. Antisense oligonucleotides usually are labelled with fluorophores or with radionuclides.
of RNA are known as antisense olignonucelotides. Usually, a segment that is about 15-20 bases long is sufficient to confer specificity to the mRNA of interest. In vitro this works well, because the cells or tissue can be bathed in these labelled RNA probes and then subsequently washed to remove any RNA probe that has not hybridized to a target mRNA molecule.
In vivo, this approach has been largely unsuccessful so far, due to problems with stability of the oligonucleotides in the plasma, delivery into cells and most problematic of all, clearance of non-hybridized oligonucleotides to allow imaging of the oligonucleotides that are specifically bound to the target mRNA (Younes et al 2002 , Tavitian et al 1998 . Another problem is the relatively low number of mRNA molecules per cell (tens to hundreds) for the expression of many genes of interest. However, research continues in this area as oligonucleotides have promise not only as imaging agents, but also as therapeutic agents, should these issues be solved.
Imaging gene expression-reporter gene methods
To date, a much more successful approach to in vivo imaging of gene expression has been to use the concept of reporter genes (figure 6). Reporter genes are genes whose protein product can be imaged (e.g., receptors or enzymes) using the methods that were described earlier. By genetically modifying cells, this reporter gene is placed under control of the same promoter or 'switch' that drives the expression of the gene that one wishes to image. Cells expressing the gene of interest, will therefore also express the reporter gene. Under many conditions, there (table 2) are driven by the same promoter. When the gene of interest is expressed, the reporter gene is also expressed and mRNA molecules corresponding to both genes are produced. The levels of the mRNA for the two genes will be proportional to each other. The protein product of the reporter gene is something that can be imaged (for example an enzyme or a receptor) and its concentration, in the absence of any other sources for that protein, will be proportional to the reporter gene mRNA concentrations and hence also to the gene of interest mRNA concentrations.
will be proportionality (although not necessarily a 1:1 relationship) between the expression levels of the two genes. By monitoring the protein product of the reporter gene with in vivo imaging, a signal that is proportional to the expression of the reporter gene and therefore the expression of the gene of interest is obtained. In general, the reporter gene should be something that does not naturally occur in the organism or tissues being studied, and should also be non-antigenic and non-toxic. Reporter gene systems have been developed for a range of imaging modalities (Weissleder and Mahmood 2001) and some of the most commonly employed ones are summarized in table 2. In all cases, the reporter gene needs to be introduced into the cells or organisms that are to be imaged. Although this is a limiting feature of the approach, it still offers many opportunities for studying biologic systems. In animal models it can be used for studying gene delivery methods using viruses, liposomes, naked DNA or other approaches being investigated for gene therapy (Meyer and Finer 2001) . It can also be introduced into the genome of infectious agents, such as bacteria and viruses, so that infection can be tracked in animal models. Another possibility is to introduce reporter genes into cancer cell lines, so that cancer cells and their progeny can be tracked in xenograft and transplant tumour models. Finally, specific genes of interest can be linked with reporter genes in transgenic animals and the expression of those genes followed in vivo over the lifetime of the animal. The major human applications will be in providing a method to monitor the effectiveness of gene therapy by imaging the location, magnitude and time course of a gene that is introduced for therapeutic purposes .
The optical approaches are the most straightforward. A number of fluorescent proteins have been isolated from living organisms and the gene that encodes for these proteins can be used as the reporter gene (Zhang et al 2002a) . Further optimization of the light yield and wavelength of emission of these fluorescent proteins have been achieved by mutations in the naturally occurring genes. Green fluorescent protein (GFP) is perhaps the best known of these proteins, although for in vivo imaging, a red fluorescent protein such as mRFP1 (Campbell et al 2002) , with an excitation peak of 584 nm and an emission peak of 607 nm, has far superior tissue penetration and is preferred. The reporter gene (and hence gene of interest) can be found in an animal just by illuminating it with the appropriate wavelength fluorescence light to excite the fluorescent protein (Yang et al 2000) . Another optical approach uses reporter genes that encode for enzymes that can lead to bioluminescence (Contag and Bachmann 2002) . The most common system uses a gene from the firefly that encodes for an enzyme called luciferase. In the presence of oxygen and ATP, and a small molecule substrate called luciferin, bioluminescence is generated with a peak wavelength of about 560 nm. Upon injection, luciferin distributes rapidly throughout all the cells of the body, and where it encounters the luciferase enzyme, light is produced. The luciferase enzyme is only present in cells expressing the reporter gene and hence expressing the gene of interest. Again, mutations have been made to the luciferase gene and bioluminescent genes from other organisms are being studied (Greer and Szalay 2002) to find bioluminescence that is of an optimal wavelength (the optical window is around 700-900 nm) for in vivo imaging in small animals.
The optical methods, while quite simple, are currently not very quantitative due to the problems of the strong dependence of signal intensity on source depth. Furthermore, except for some specific applications close to the skin surface or areas that can be reached by endoscopes, these methods are also not very translatable to the clinic. Hence, there has been considerable interest in using nuclear imaging and MRI techniques to image gene expression. These employ similar approaches, except that the reporter gene in this case encodes for something that can accumulate or activate an exogenously administered contrast agent. The reporter gene could, for example, encode for an enzyme that traps a small-molecule substrate labelled with a radionuclide (Gambhir et al 2000 , Blasberg 2002b ), or encode for a receptor that can internalize super-paramagnetic iron oxide particles in cells and hence change the T2 relaxation time in an MR image . In all cases, the approach is the same, relying on a proportional relationship between the image intensity, the protein product of the reporter gene, the expression of the reporter gene and the expression of a gene of interest. The details differ only in the method by which image contrast is generated as summarized in table 2. It is also possible to couple multiple reporter genes to the same gene of interest, so that the same animal could be imaged with multiple different imaging modalities (Ray et al 2003 . Reporter gene approaches are now being widely used, especially with optical and nuclear imaging techniques, to study animal models of cancer and infectious disease, and to develop and evaluate new strategies for gene therapy.
General considerations
The broad categories described above represent just some of the approaches being pursued to develop targeted contrast agents for molecular or genomic imaging. The type of biomolecule and contrast mechanism that should be utilized to address a specific biologic question depends on many factors, including the spatial and temporal resolution desired, the location and distribution of the target (intravascular, extracellular or intracellular; deep inside subject or superficial; focal distribution, or widely distributed in body), the concentration of the target, the specificity that can be achieved and the source and locations of background and non-specific signal. Several research groups are exploring novel amplification strategies that will enable lower levels of protein or gene expression to be detected in vivo (Zhang et al 2002b) . Recent research in contrast agent development has dramatically extended the reach of non-invasive imaging technologies and is now allowing us to explore a wide range of proteins and genes that are known to be important in disease. Future developments are expected to extend this range even further through the identification of new targets, new contrast agents to image these targets and methods to amplify the signal to allow more sensitive detection of these targets.
It is also important to recognize that there are many indirect molecular and genomic imaging approaches (for example, measuring vascular density with ultrasound, CT or MRI as an indirect marker of angiogenesis) using less specific, but often more easily applied imaging techniques or with readily available clinical contrast agents. Such studies, typically employing anatomic, physiologic or metabolic imaging, can yield important insights into the underlying biology. However, data must be analysed with some caution, due to the complex nature of biological systems, and the possibility that signal changes can be a result of complex interactions of multiple genes and proteins. Similarly, the absence of a signal change with such an indirect measurement may be a result of system redundancy, switching to alternate pathways, or other forms of regulation at the system level, and does not necessarily imply that there are no significant changes in the specific gene, protein or molecular pathway of interest.
Imaging technology and systems
Dramatic advances in imaging technology, especially for small-animal imaging, have been an important driving force in establishing the field of molecular and genomic imaging. Traditional radiologic imaging modalities such as MRI, CT, ultrasound, SPECT and PET have all been 'reinvented' as tools for the modern biologist to track laboratory animal models of disease non-invasively. Furthermore, optical techniques, previously the domain of microscopic studies of thin tissue sections or cells, have been successfully extended into the whole animal (mouse) setting using wavelengths of light in the near infrared that can penetrate through more than 1 cm of tissue. While advances have been rapid, many challenges remain. Improvements in resolution, sensitivity and quantitative accuracy for small-animal imaging are possible with all imaging techniques. In conjunction with advances in targeted contrast agent development, much lower levels of protein or gene expression should be accessible by imaging approaches in the future. Techniques to image multiple genes or proteins at once will be important, as will the ability to map images specific to a gene or protein accurately onto a high resolution anatomic image to understand the origin of the observed signal and to facilitate direct and imageguided interventions where appropriate. Finally, these powerful tools currently have limited distribution and availability in the biological sciences. Partly this is a matter of embracing a new community of users and demonstrating the power of these imaging technologies to address questions that are of interest to them, and partly this is due to perceptions and certain realities regarding the complexity and cost of these technologies. However, it seems likely that the rapid growth of the molecular imaging field will drive the technology forward, evolving compact, low-cost and easy-to-use imaging systems that can provide high sensitivity, high resolution, quantitative images of specific biological targets in vivo. In this section, technologic advances related to in vivo small-animal imaging with each of the major imaging modalities will be briefly reviewed, and where possible, future challenges identified.
X-ray computed tomography
In vivo imaging of small animals with CT has a critical role to play in the evolution of molecular imaging (Ritman 2002 , Paulus et al 2000a . While for the most part, targeted contrast agents for direct molecular imaging by CT are limited by the concentration of these agents required for a detectable signal change (Ritman 2002 , Idee et al 2002 , conventional anatomic CT with non-specific contrast agents is a relatively straightforward way to obtain high-resolution anatomic information which is often important to analyse molecular imaging studies obtained using other modalities (especially nuclear and optical approaches). MicroCT is also a valuable tool for indirect approaches to molecular imaging (Ritman 2002) , for example, imaging changes in vascular density and permeability associated with angiogenesis and anti-angiogenic therapeutics. MicroCT is the method of choice for tracking changes in diseases that affect bone. The high resolution of microCT allows very sensitive detection of bone growth, destruction, remodelling and changes in bone density, and is therefore ideally suited for studying the consequences of diseases such as osteoporosis and rheumatoid arthritis, and for evaluating the effects of therapeutic interventions on the progression of these diseases. MicroCT also has the potential to be used as a fairly high-throughput imaging technique and investigators are considering its use for phenotypic screening in genetically manipulated mice (Paulus et al 2000b) .
The development of systems for in vivo small-animal microCT imaging has evolved largely from ultra-high resolution microtomography systems designed for specimen imaging (Flannery et al 1987, Machin and Webb 1994) . Several groups have now developed in vivo microCT systems (Paulus et al 1999 and a number of companies also offer commercial products. Some of the specific and continuing challenges in moving from specimen imaging to in vivo imaging have been to reduce the radiation dose, deal with motion artefacts, change the system geometry to allow the animal to be placed horizontally and remain stationary during scanning and to decrease imaging time.
To date, microCT systems have made use of 2D x-ray detectors developed for specimen imaging or digital mammography, and systems generally acquire data in conebeam geometries. This imaging geometry is relatively simple to implement and the 3D collection makes the most efficient use of the relatively modest x-ray flux that is emitted by the compact microfocus fixed anode x-ray tubes generally employed in these applications (Flynn et al 1994) . These low-power tubes are supported by compact power supplies and the small x-ray focal spot size offers the potential for very high spatial resolution. At the same time, the anode current (and hence number of x-rays produced) of these compact tubes is limited by the small focal spot size and the fixed anode design when operated continuously for CT acquisition. Typical x-ray tube parameters used in microCT systems are focal spot sizes in the range of 10-100 microns, and tube currents of at most a few mA at an anode voltage of 25-75 kV. Most commonly, tungsten anode tubes are being utilized. For CT imaging, the x-ray tube is generally operated continuously with a shutter to control when x-rays irradiate the object. A resolution of tens of microns is achievable in some microCT systems, however there are significant impediments to actually obtaining this spatial resolution in a live animal as discussed below. A range of detector technologies are being used, including both direct and indirect x-ray detectors. The most common approach is to use gadolinium oxysulfide (GOS) screens, fibre-optically coupled to a CCD camera , Paulus et al 2000a . Figure 7 shows an example of in vivo images obtained on a commercial microCT system based on this technology. Amorphous silicon (a-Si) detectors, CMOS and photodiode arrays are also being coupled to GOS screens, and the use of columnar CsI(Tl) screens to reduce light spread in the photon converter looks promising (Nagarkar et al 1998) . Finally, direct x-ray detectors based on amorphous selenium detectors also have been utilized for microCT (Goertzen et al 2002) , and high-efficiency detectors based on PbI and HgI 2 are under development (Street et al 2002) .
One of the most challenging aspects of in vivo microCT imaging relates to the radiation dose received by the subject. Measurements by us and others (Paulus et al 2000a , Goertzen 2003 show typical radiation doses in the range of 10-50 cGy for a single microCT study. These doses were measured using small thermoluminescent dosimeters implanted into mice and also confirmed using simulations. The LD50/30 for mice (the dose at which 50% of mice die without medical intervention) is roughly 5 Gy, so a single microCT scan can represent as much as 10% of the LD50/30. Furthermore, with the exception of phenotypic screening studies, one of the major applications for non-invasive imaging technologies is to follow the same animal longitudinally. Animals will therefore often be part of imaging protocols that involve multiple scans, perhaps as many as 8-12 scans within a single animal over a period of several weeks. In this case, the cumulative dose becomes extremely high. Not surprisingly, the biologic effects depend not only just on the total dose delivered, but also on the time schedule over which it is delivered. The effects are also a complex mix of the long-term effects of radiation-induced damage (proportional to the delivered dose), and stimulation of DNA repair mechanisms, free-radical detoxification, immune response and apoptosis (Feinendegen and Pollycove 2001) . These latter stimulatory effects are generally seen at doses in the range of 10-50 cGy and can last from hours to weeks. The low-dose radiation literature demonstrates many cases of significant and potentially confounding biologic effects at the radiation doses that are currently being delivered by in vivo microCT imaging. For example, total-body irradiation with cumulative doses of >50 cGy to the BALB/c mouse delivered in 7 days or less results in a significant increase in the formation of ovarian tumours (Yuhas 1974) . On the other hand, single doses of 20 cGy in KDH-8 (hepatoma) tumours in rats dramatically suppress metastatic colonization of the lung and lymph nodes (Hashimoto et al 1999) . Even doses as low as 1 cGy are reported to reduce tumour volume in a mouse model of lymphoma with respect to unirradiated controls (Bhattacharjee and Ito 2001) . In a non-cancer example, 50 cGy total-body irradiation of non-obese diabetic (NOD) mice suppresses progression of type I diabetes in these animals (Takahashi et al 2000) . Given this data, the clearest and perhaps most critical challenge is to develop the capability to acquire high quality microCT images at much lower radiation doses. In addition, for any specific animal model that is being studied with longitudinal microCT imaging, it would be prudent to maintain unirradiated control animals until radiation-induced effects can be eliminated as a confounding variable for that particular model. Improvements in the detector technology, in optimization of the x-ray spectrum and imaging geometry, and the use of contrast agents can all potentially lead to improvements in signal-to-noise or contrast-to-noise that will allow reduction in the radiation dose, but it will likely still require that a sacrifice in spatial resolution be made to allow the order of magnitude dose reductions that are required for longitudinal imaging. However, in the context of in vivo imaging, where cardiac, respiratory and other tissue motion significantly degrade resolution beyond what microCT systems are currently capable of, a reduction in system resolution may not have a significant impact on the information content of the images. Where high resolution is required, one-time imaging of euthanized animals can achieve extremely high spatial resolution (tens of microns) without concerns related to radiation dose or physiologic motion (Ritman 2002) .
Physiologic motion due to respiration and the beating of the heart can be reduced by gated data acquisition and this is being actively pursued by a number of microCT companies. Given the high heart rate in a mouse (typically 400-500 beats per minute), control of the x-ray shutter, or the detector, at the millisecond level becomes necessary. The biggest drawback to gating, other than the added complexity, is that the imaging time will likely be extended, because acquisition can only occur during the selected part of the respiratory and cardiac cycles. In human CT scanners, motion is minimized by extremely rapid imaging and the use of powerful x-ray tubes and fast detectors. A similar approach could be employed in animal studies, however the x-ray tube and gantry requirements would then lead to a relatively large and expensive system that may not be compatible with the biology laboratory environment.
Current microCT system designs are largely based on cone-beam geometry and generally use the Feldkamp algorithm (Feldkamp et al 1984) to reconstruct the data acquired from a single circular orbit. However, the projection data are not complete, and significant artefacts result when the cone angle is large. These artefacts increase in magnitude towards the axial extremes of the field of view. In specimen imaging, artefacts are often small because the specimen is small compared with the detector dimensions and the cone angle can be small. For whole mouse imaging, larger cone angles are used and the subject often extends throughout the entire axial field of view. Artefacts are of particular significance when the microCT data are going to be mapped with the data from another modality and where geometric distortions could lead to a misinterpretation of the data. In addition, the cone-beam geometry is very prone to the detection of scattered radiation, and microCT scanners currently do little to try and reduce or eliminate scattered x-ray flux. It is therefore possible that alternative imaging geometries may give improved results (for example, helical scanning with a much reduced cone angle and some form of collimation to reduce scatter) for in vivo mouse imaging with CT.
Nuclear imaging
The primary advantage of radioactive assays (whether in vivo, ex vivo or in vitro) is their exquisite sensitivity, and the ability, with appropriate care, of radiation detection systems to provide quantitative measurements of radioactivity concentrations deep inside tissue. Radiolabelled tracers have a long history of being used to elucidate physiology, metabolic pathways and molecular targets (Early 1995) , and provide a high sensitivity tool for molecular imaging studies. A very large number of radiolabelled tracers have been developed to probe specific biological targets and functions (Welch and Redvanly 2002), and a growing number are moving into clinical use. An important strength is the availability of radionuclides of biologically relevant elements, particularly carbon, allowing contrast agents to be labelled by direct isotopic substitution. This allows small biomolecules (many drugs, receptor ligands etc . . . ) to be labelled without changing their biochemical properties. Another powerful approach is to create analog radiotracers, in which deliberate chemical changes are made to a biologically active molecule to isolate specific pathways or cause specific trapping of a radiotracer in cells expressing the target of choice. Analog radiotracers are also designed to allow the use of isotopes of elements that are not found within the molecule of interest, but that have good imaging properties. Larger biomolecules (peptides, antibodies, RNA, synthetic macromolecules) are also readily labelled with a wide range of radionuclides that have excellent properties for imaging. A list of the major radionuclides that are currently being used for in vivo nuclear imaging is provided in table 3. A further advantage is that nuclear imaging approaches are readily translated to the clinic, as the majority of the listed radionuclides produce photons with sufficient tissue penetration for studies in man. Disadvantages of nuclear imaging approaches include obvious factors such as the involvement of ionizing radiation, and more subtle factors such as the fact that radioactive decay cannot be controlled, hence there is always non-specific background signal present in an image due to non-specific binding of radiotracers, residual radiotracer in the circulation and routes of excretion. Nuclear imaging techniques include high resolution (<100 micron) ex vivo autoradiographic techniques using film, phosphor storage plates or real time autoradiographic systems (Charon et al 1998) , and in vivo methods using radionuclides that produce appropriate energy photons (gamma-rays, annihilation photons or characteristic x-rays with energies in the range of 25-511 keV) during decay. The in vivo methods are further broken up into single photon imaging that utilize radionuclides with single or multiple uncorrelated gamma ray emissions and PET in which radionuclides decay by positron emission resulting in two simultaneous annihilation photons emitted back-to-back . Single photon imaging is accomplished using a gamma camera in which the radioactivity distribution within the object of interest is projected through a collimator to form an image on the detector. Resolution and signal-to-noise are generally dominated by the collimator design. Multiple gamma camera heads can be mounted on a gantry to improve sensitivity, and by rotating the head(s) about the object, tomographic studies (single photon emission computed tomography or SPECT) can be performed. PET does not require physical collimation due to the back-toback nature of the annihilation photons that define the direction of emission. PET scanners typically consist of rings of small detector elements in a cylindrical geometry, simultaneously providing projection views of the radioactivity distribution from many different directions that are then reconstructed into tomographic images. Because no physical collimation is required, the sensitivity is much higher (typically 10 2 to 10 3 times higher) than a SPECT system. However, single-photon emitting radionuclides are generally more readily available than positron-emitting radionuclides, as many of the latter have short half-lives.
The development of higher resolution and higher sensitivity animal PET and SPECT systems is allowing molecular and genomic imaging approaches, traditionally approached by ex vivo autoradiographic methods, to be translated in vivo into animal models of disease Ivanovic 1999, Cherry and Gambhir 2001) . Dramatic improvements in image quality have been achieved by using novel detector and collimation approaches, and by exploiting the more favourable imaging environment found in small-animal imaging. Compared to imaging of human subjects, there is less scatter and attenuation of the photons emitted within the object, and a large solid angle for detection can be achieved with a relatively small detector surface area brought close to the object. This has allowed a broad range of detector technologies to be explored for molecular imaging applications including position-sensitive and multichannel photomultiplier tubes (Cherry et al 1997, Miyaoka et and multiwire proportional chambers with appropriate converters (Jeavons et al 1999 , Bruyndonckx et al 1997 . Careful system design has enabled in vivo images with around 1 mm 3 volumetric spatial resolution to be achieved with both PET and SPECT (Tai et al 2003 , Jeavons et al 1999 . A number of companies are now offering commercial small-animal PET and SPECT systems (Tai et al 2001 , Jeavons et al 1999 .
These early small-animal nuclear imaging systems have achieved considerable success in visualizing specific molecular targets or reporter gene expression as illustrated in figure 8 . However, significant challenges and question marks remain. While the high sensitivity of nuclear imaging techniques is often touted, there is a paucity of data showing what radiotracer accumulation, relative to non-specific radiotracer distribution, is required to detect or accurately quantify a signal with these new imaging systems. This is important information for the purposes of developing new targeted radiotracers and planning molecular imaging experiments, and would assist us in estimating how many copies of a particular mRNA or protein there needs to be per resolution element for a signal to be detectable. Right now, this information is largely anecdotal, and it is clear that specific data could easily be accumulated in carefully designed phantom, cell culture and tumour xenograft studies.
A second challenge relates to integrating advances in the imaging technology with advances in 3D image reconstruction. It has become increasingly clear that accurate modelling of the physics and statistics of the data collection process and the use of this modelling within the reconstruction algorithm can pay very substantial dividends in terms of spatial resolution, signal-to-noise or both (Qi et al 1998 , Johnson et al 1997 , Reader et al 2002 . Examples of modelling of the physics would include factors such as collimator penetration (SPECT), positron range (PET), photon acolinearity (PET), object scatter, detector or collimator scatter, depth of interaction or parallax effects (PET) and detector geometry (e.g., gaps, variations in solid angle with source position etc). What is yet to be determined is how accurate the modelling needs to be, which parts of the modelling are most important and perhaps how knowledge of the reconstruction process and its sensitivity to the model parameters can be used to assist in future scanner design to improve the accuracy and quality of the reconstructed image, and by optimizing symmetry, reduce the reconstruction time.
In small-animal SPECT, the limitations currently relate largely to sensitivity. Traditional approaches have employed pinhole collimation to achieve high spatial resolution (Weber and Ivanovic 1999) , but this provides a limited field of view or limited sensitivity. A number of novel collimation techniques are being explored that can simultaneously provide high resolution and relatively high sensitivity by using multiple pinholes (Ochoa et al 1997) (Liu et al 2002) or coded aperture methods (Meikle et al 2002 , Accorsi et al 2001 . Significant gains may also be realized by using radionuclides with lower energy emissions (e.g., the characteristic x-rays from 125 I, 27-35 keV) where collimation requires less absorbing material, and collimators with better trade-offs between spatial resolution and sensitivity can be built , Weisenberger et al 1998 . In most small-animal systems, pixellated scintillation detectors are being used (typically NaI(Tl) or CsI(Tl)), with the conversion of optical light to electrons being achieved in photomultiplier tubes or photodiodes , Meikle et al 2002 , Weisenberger et al 1998 . New detector development is also being pursued by a number of groups. A SPECT system has been constructed based on direct detection of gamma rays with cadmium zinc telluride, a semiconductor material , and Compton camera approaches, in which the direction of the incident gamma ray is determined not by physical collimation, but by using energy and position information from a two layer detector that exploits Compton interactions, continues to be explored in the light of detector advances (Meier et al 2002) .
In PET, small-animal systems are still largely detector limited. Detector materials and geometries that simultaneously provide highly efficient detection and unambiguous localization of the 511 keV annihilation photons do not currently exist. This is largely due to the fact that at this energy, even using the densest detector materials currently available, annihilation photons have a high probability of Compton interactions in which they scatter inside the detector leading to ambiguity in determining the initial interaction location. Thin detectors can be used to minimize detection of the scattered gamma rays, but at the expense of efficiency. With thick detectors, it is necessary to also determine the depth of interaction in the scintillator to avoid unacceptable resolution degradation through parallax errors. All of the small-animal PET systems currently in existence make trade-offs in resolution and sensitivity and none are yet capable of simultaneously achieving high sensitivity (>20% of all emitted annihilation photon pairs detected) and high resolution (<1 mm spatial localization with the detector material), although such performance should theoretically be possible.
Ultimately, PET, unlike SPECT, has some fundamental restrictions on the resolution that can be achieved. This is due to the range of the positron before annihilation (the image that is produced is actually an image of the annihilation locations, not the location of the decaying radionuclide) and the slight non-colinearity (±0.25
• ) of the two 511 keV photons due to residual momentum of the positron and the electron at the time of annihilation. Positron range effects vary from radionuclide to radionuclide and depend on the energy spectrum of the emitted positrons (Derenzo 1979, Levin and Hoffman 1999) . Non-colinearity effects depend on the separation of the detectors and are minimized in small-animal studies where the detectors can be placed close together. Nonetheless, even with the lowest energy positron emitters (e.g., 18 F or 64 Cu) and a detector separation of 10 cm, these effects will blur the resulting image by several hundred microns. However, the blurring kernels due to these factors are easily calculated or simulated with high precision, and they can therefore be used in the system model within the reconstruction algorithm to partially compensate for these effects. The degree of success will depend on the statistical quality of the acquired data, and it is not yet known, in practical imaging situations, what the limiting spatial resolution of PET for small-animal imaging will be. However, several groups have now clearly indicated the ability to obtain in vivo animal images at a resolution of around 1 mm (Tai et al 2003 , Jeavons et al 1999 .
A final important challenge in nuclear imaging relates to quantification. One of the advantages of nuclear imaging, say, compared to optical imaging, is that the radiation involved is highly penetrating, and so the dependence of the detected signal on the depth at which it is emitted is fairly small. Even without correction for scatter and attenuation, nuclear images within small animals can exhibit fairly high quantitative accuracy in specific circumstances and with the appropriate calibration object. Many in the field strive for more accurate and more generalizable quantification, for example, by employing transmission scans to compute an attenuation correction and Monte Carlo simulations or analytic calculations to estimate scatter contributions. Although a laudable goal (and in imaging humans, definitely a necessary one), it dramatically increases the complexity of performing nuclear imaging studies in the biology lab. One of the challenges before the field is to determine what level of sophistication is really required to produce acceptable quantification of nuclear imaging studies for smallanimal imaging, where scatter and attenuation effects are generally small, and to find fast and transparent means to achieve this level of quantification, without requiring additional scans or sophisticated user expertise.
Optical imaging
There has been tremendous growth in the use of optical approaches for in vivo imaging of small laboratory animals. This is in part due to the accessibility of optical approaches, and also in part because of their extremely high sensitivity. Light is both scattered and absorbed in tissues, but there is an absorption minimum corresponding to wavelengths in the approximate range of 700-950 nm (Chance 1998) . At these wavelengths, the light is still readily scattered, but the absorption length is on the order of several centimetres. Thus, light emitted from deep inside a small animal has a reasonable probability of reaching the surface for external detection. Although this light has in general scattered many times when it reaches the surface, some positional information is retained based on the intensity, spatial distribution and spectral distribution of the emitted light (Rice et al 2001) . This region of the electromagnetic spectrum is known as the 'optical window' because of the more favourable characteristics for imaging through tissue.
At the present time, most studies are based on imaging the intensity of the emitted light at the surface of the animal with straightforward detector systems that are amenable for use in biology labs and have the capability of relatively high throughput. Two distinct contrast mechanisms are being used for molecular and genomic imaging studies, one involving fluorescence , and the other involving bioluminescence (Contag and Bachmann 2002) .
In fluorescence imaging, an external light source, either a laser, or a broadband source (e.g., a mercury lamp) with an appropriate low-pass filter, is used to excite fluorescent molecules inside the subject. These fluorescent molecules may be genetically engineered into a mouse, for example by incorporating the gene for a fluorescent protein as a reporter gene. GFP has been widely used in this manner for cell culture and tissue slice experiments, but is less well suited for in vivo use, because of the relatively short excitation (peak ∼470-490 nm) and emission (peak ∼510 nm) wavelengths that place it outside the optical window and in a part of the spectrum where there is significant autofluorescence of tissue components. Despite these difficulties, GFP has been used successfully for some in vivo imaging studies (Yang et al 2000) . Subsequently, GFP mutants and other fluorescent proteins have been discovered that have excitation and emission spectra better suited to in vivo imaging (Tsien 1998 , Matz et al 1999 , Campbell et al 2002 . Another approach to introducing fluorescent molecules into an animal is to use fluorophores (or more recently, fluorescent particles known as quantum dots) as labels on biologically interesting molecules . This is analogous to radionuclide labelling for nuclear imaging, although the approach generally is limited to the labelling of larger biomolecules where the size of the fluorophore does not interfere with the biological activity of the agent. Again, fluorophores that are excited and emit in or close to the optical window are preferred for good penetration depth and large amplitude signals. Table 4 provides data on a number of fluorophores that are being used for in vivo studies and an example of a study carried out with a near infrared fluorescence probe is shown in figure 9 . There are two key advantages to fluorescence imaging. Firstly, many of the fluorophores used have high quantum yields, leading to robust signals when using appropriate illumination and acquisition times. Secondly, as described earlier, the fluorescence emission can be activated by specific biologic molecules or events. This eliminates signal from contrast agent that is circulating and from paths of excretion (a limiting problem for radiotracers), reducing background 'noise'. This allows very low concentrations (subnanomolar, and with some activatable agents, picomolar or better) of enzymes to be detected. The disadvantage of fluorescence imaging is that there is autofluorescence from tissue that forms a background that ultimately limits detection sensitivity. A second problem is that light has to get into the animal (to excite the fluorescent molecules) and back out again (to reach the detector). Because of the high degree of scattering of both the excitation and emission light, it is not possible to excite and isolate the fluorescence within very small volumes of tissue inside the animal. As a consequence of the strong dependence on depth of both the intensity of the excitation light and the detection of the emission light, quantitative analysis of the images, in all but the very simplest cases of a small point emitter, becomes extremely difficult.
Fluorescence imaging can be carried out using conventional CCD cameras. The use of back-illuminated CCDs, and cooling, enhances sensitivity and signal-to-noise ratio, but for many studies general purpose scientific CCD cameras are sufficient, because detection sensitivity is limited by autofluorescence, rather than by the noise characteristics of the detector. A simple black box and a lens coupled CCD camera connected to a computer can yield acceptable fluorescence images showing the light distribution on the surface of the animal in just a few seconds or minutes (Weissleder et al 1999) .
The second approach to in vivo optical imaging involves introducing reporter genes that encode for enzymes (known as luciferases) that can catalyze a light-producing reaction. This process is called bioluminescence and luciferases are found in organisms such as fireflies, glow worms and jellyfish (Greer and Szalay 2002) . The most commonly used reporter gene for imaging is the one that encodes for firefly luciferase (Contag et al 1998) . This gene is introduced as a reporter gene as described previously. Just prior to imaging, animals are injected with the substrate for the enzyme. In the case of the firefly luciferase the substrate is luciferin, a small molecule that rapidly distributes throughout the whole body of the mouse after intravenous or intraperitoneal injection. In cells that are expressing the luciferase reporter gene, the luciferin, in the presence of oxygen and ATP, is converted to oxyluciferin with the emission of light (peak at 560 nm). The reaction is catalyzed by the luciferase enzyme and does not occur to any significant extent when luciferase is absent. The generation of an optical signal is therefore specific to cells that contain the reporter gene. Mutations of the naturally occurring firefly gene has resulted in a shifting of the emission peak to around 620 nm, with . 62 1862-7) .) significant amounts of light being emitted in the 550-700 nm range, improving its sensitivity for in vivo imaging studies (Contag and Bachmann 2002) .
The advantage of the bioluminescence approach is that there is no need for external light stimulation. There is no problem, therefore, in depth of penetration of the excitation light as there is with fluorescence, and there is no autofluorescence background to contend with. The disadvantage is that this approach is limited to studying genetically manipulated cells or transgenic mice, or infectious agents such as bacteria and viruses, as the reporter gene has to be introduced to the organism that is to be studied. Also, the bioluminescence signals are typically very weak. These low signals require the use of high quantum efficiency CCDs that are cooled to minimize dark current over the integration time required to obtain an image (typically a few minutes). Significant improvements in the sensitivity of bioluminescence imaging have been facilitated by the improvement of CCD technology, specifically the introduction of back-thinned CCDs and anti-reflective coatings that significantly boost the quantum efficiency (Contag and Bachmann 2002 ). An example of in vivo bioluminescence imaging is shown in figure 10 .
The biggest efforts in optical imaging at the present time are devoted to moving from a single image of the light intensity projected at the surface of the animal to tomographic images that provide information on the distribution of the light source in 3D. This involves acquiring data from a small number of views such that the light intensity across the surface of the entire mouse can be mapped. For fluorescence imaging, the illumination source can also be moved across the animal to provide additional information. Using models of light propagation in tissue (Arridge 1999) , it is possible to estimate the distribution of bioluminescence or fluorescence in the animal, although a wide number of assumptions are generally made in the model formulation to make the reconstruction tractable and the solution well behaved. Extending the work of researchers in the field of diffuse optical tomography to incorporate fluorescence, it has recently become possible to reconstruct 3D images showing the location of fluorescent contrast agents with both good spatial resolution (around 1 mm) and high sensitivity (nanomolar concentrations) (Ntziachristos and Weissleder 2001 , Graves et al 2003 . Although these initial results are extremely promising and exciting, examples are largely confined to studies in which the distribution of the fluorescent contrast agent is highly localized in a small volume such as a tumour and is activated only by tumour specific enzymes. One of the challenges is to demonstrate that fluorescence tomography can also be achieved with similar resolution and sensitivity in the more general case where the fluorescent contrast agent is more widely distributed within the animal.
Clear opportunities exist for improving optical imaging of the distribution of fluorescently labelled contrast agents and fluorescent or bioluminescent reporter genes. Progress can be expected in better modelling of light propagation through different tissue types, incorporating information on tissue boundaries and the contours of the mouse (perhaps from anatomic images of the same animal or a standardized mouse atlas), and optimizing the geometry and efficiency for excitation (for fluorescence) and light collection. In addition, a number of groups are exploring how other properties of light can be exploited, for example the use of a frequency modulated excitation source (Sevick-Muraca et al 2002) and the depth dependence of the spectral characteristics of the emitted light (Zavattini 2003) . Further improvements in CCD camera technology (quantum efficiency, noise, detector area etc . . . ) will be important, particularly for detection of relatively low levels of gene expression using bioluminescent approaches. Very fast, gated, optical imaging detectors will be beneficial for studies involving frequency modulation or lifetime measurements.
Ultrasound
Ultrasound also has been successfully adapted as a tool for small-animal imaging and together with the development of novel echogenic contrast agents promises to add molecular imaging capability in a number of very important areas. Advantages of ultrasound include real-time imaging, portability, low cost, high spatial resolution and the absence of ionizing radiation. One of the key trade-offs in ultrasound is between acoustic frequency, depth of penetration, and spatial resolution. In small-animal models, a depth of penetration of 1-2 cm is generally sufficient, allowing high frequencies on the order of 20-60 MHz to be used. This leads to a spatial resolution in the range of tens of microns. One of the really unique capabilities Goertzen et al (2002 Phys. Med. Biol. 47 4315-28).) of ultrasound is in developmental studies (Turnbull 1999) , particularly pre-natal studies in genetically manipulated mice (figure 11). Genetic manipulations often result in embryonic lethal phenotypes that do not survive to birth, hence the ability to determine phenotypes in utero is extremely important. High-resolution embryonic imaging cannot be performed noninvasively with any other modality at the present time due to fetal motion, which requires very fast acquisition. The real-time nature of ultrasound is also of importance in studying cardiac anatomy and function in rodents, and opens up opportunities for image-guided interventions in animal models.
The capabilities of ultrasound go far beyond anatomic imaging for phenotypic analysis. High frequency Doppler flow mapping enables quantitative measurements of blood flow not only in major vessels, but importantly, also in the microcirculation (Stith et al 1996) . Contrast agents are being developed that promise to give ultrasound a major role in molecular imaging and therapeutics Wickline 2001, Dayton and . In their simplest form, these contrast agents are small bubbles (typically 1-10 microns in diameter) in which a lipid or albumin shell is filled with a gas such as perfluoropropane. These microbubbles produce very strong ultrasound echoes due to differences in their compressibility and density compared to surrounding biologic tissues. In fact a standard clinical ultrasound system can detect the echo from an individual microbubble, thus in principle, the sensitivity for detection of such contrast agents is extremely high. Microbubbles are already in clinical use, where they are used to detect small vessels and capillary beds by enhancing the signal from the small volume of blood. In addition, microbubbles have interesting non-linear oscillation properties in response to ultrasound radiation. With appropriate acoustic pressure, these bubbles can actually burst. By applying local acoustic pressure to burst the bubbles, the contrast agent can be selectively destroyed within a small volume of tissue. By imaging the return of the signal as blood containing intact contrast agent flows into the region, it is possible to quantify important physiologic parameters such as blood velocity, blood flow and blood volume in the microvasculature. These measurements can be repeated over and over for a single contrast agent injection with high spatial and temporal resolution. Research is now in progress to decorate the outside of these bubbles with targeting molecules such that microbubbles can be targeted towards specific cell-surface receptors (Lindner et al 2001 , Leong-Poi et al 2003 , particularly those readily accessible to an intravascular contrast agent (figure 12). In addition to the use of ultrasound and microbubbles for molecular imaging approaches, there are also opportunities to combine this with therapeutics. For example, microbubbles could also be used to carry a drug to a target, using the targeting on the surface of the bubble to enhance concentration of the drug at the target. With appropriate acoustic pressure, it is possible to burst the bubbles, therefore delivering a drug or gene payload in site-specific manner (Shohet et al 2000) .
Several companies are now producing ultrasound systems that have characteristics suitable for small-animal imaging. An example of a system developed specifically for mouse micro-imaging is given in Foster et al (2002) . One area of active research in ultrasound instrumentation is the development of high performance phased array transducers for use at these high frequencies. A particular challenge is to create transducers with high bandwidth. Other areas of active research include new signal processing approaches for high frequency colour flow imaging (Kruse and Ferrara 2002) and methods for truly 3D volumetric imaging in rodents (Arbeille et al 2000) . For molecular imaging approaches and complementary drug targeting and delivery, it is important to understand and model the physics of how ultrasound contrast agents respond to incident ultrasound radiation. Due to the non-linear response of these agents, one can use pulses of ultrasound radiation to cause oscillations and ultimately fragmentation of the contrast agent as mentioned above. Radiation force can also be used to move contrast agent to the vessel wall , thus increasing the concentration of contrast agent in close proximity to the endothelial cells. A current problem with these contrast agents, however, is the wide size distribution of the bubbles or particles, which limits how well they can be controlled. Assuming methods can be found to generate contrast agents of a specific size, it is likely that by judicious design of ultrasound 'pulse sequences', it will be possible to visualize, direct and destroy these agents in a well controlled and quantifiable manner.
Magnetic resonance imaging
MRI is one of the more mature technologies for small-animal imaging. Magnetic resonance microscopy (generally defined as imaging with a resolution of better ∼100 microns) has been around since the mid 1980s (Callaghan 1991) and has found particular applications in neuroscience Blackband 2002, Jacobs and and developmental biology (Jacobs et al 1999) . High-field magnets are introduced in small-bore animal imaging systems several years before they can be achieved for larger bore human applications, therefore these animal systems serve as important test-beds and catalysts for developing high resolution, high speed and high sensitivity pulse sequences. Most small-animal imaging is currently carried out on horizontal-bore instruments with field strengths between 4.7 T and 9.4 T and bore sizes of 20-40 cm. Research systems with field strengths as high as 11.7 T (40 cm horizontal bore) and 21.1 T (8.9 cm vertical bore) are also being evaluated for small-animal imaging (Beck et al 2002) . Higher field strengths are desirable for high-resolution imaging because the signal-to-noise ratio (SNR) is proportional to field strength, and the detected signal is proportional to the tissue volume within a voxel. A reduction in voxel size from 1 × 1 × 1 mm to 0.1 × 0.1 × 0.1 mm therefore results in a 1000-fold reduction in the detected signal.
Since SNR is only linearly proportional to field strength, higher fields only in part make up for the reduced voxel size in high resolution images. Therefore, images at resolutions of tens of microns can only be achieved with very long acquisition times, typically many hours for a whole mouse. For this reason, the very highest resolution images are usually obtained from fixed specimens, which further has the advantage of avoiding any resolution degradation due to tissue motion, and eliminating the need for careful physiologic monitoring and anaesthesia. Ex vivo imaging of fixed specimens is a very valuable tool in its own right (Johnson et al 2002) with applications in mouse phenotyping, 3D histological analysis and developmental studies, but will not be discussed further here.
In vivo images of anatomy with a spatial resolution of a few hundred microns can be achieved in several minutes with MRI when combined with appropriate physiologic gating to control cardiac and respiratory motion. Sophisticated physiologic monitoring and forced respiration systems have been developed to allow motion-free in vivo imaging and wellcontrolled physiologic status deep inside a high-field magnet (Hedlund et al 2000) . The good soft-tissue contrast achieved by well-designed pulse sequences has led to MRI becoming the method of choice for following anatomic changes in soft tissue that may be related to a disease course or an intervention. Furthermore, MRI has the ability to measure physiological parameters, including water diffusion and blood oxygenation levels (which leads to the contrast used in functional MRI to study brain activation). The addition of 'passive' contrast agents, such as Gd-DTPA, further enhances the utility of MRI, allowing vascular density, permeability and perfusion to be assessed. Another example of a passive agent is the use of Mn 2+ ions for tract-tracing studies in the brain (Pautler et al 1998) . Hyperpolarized 3 He and 129 Xe, in which a laser is used to populate a particular polarization state at much higher levels than the thermal polarization of 1 H, offer the possibility of high resolution imaging of the airways and lungs Hedlund 1996, Moller et al 1999) . Recently, hyperpolarized solutions of 13 C have also been created for imaging of the vasculature (Svensson et al 2003) . Taken together, these MRI methods provide a powerful set of tools for interrogating anatomic and physiologic changes that are a consequence of specific cellular or molecular alterations in living animals.
Of more interest in the context of this paper is the development of targeted and activatable contrast agents for MRI that offer the prospect of direct molecular imaging. These agents are based on transition metals or lanthanides that are paramagnetic and change the relaxation time (either T1 or T2) in tissue regions in which they accumulate (Aime et al 2002) . Because of the relatively low sensitivity of MR methods, compared with optical or nuclear approaches, the challenge is to get enough of the agent to the target to effect a detectable signal change, without causing toxicity. A number of clever strategies have been developed to improve detection sensitivity using activatable agents that minimize signal background , or amplification strategies that result in high levels of accumulation of paramagnetic ions at the target . With these approaches it has been possible to image transgene expression in vivo with MRI (figure 13).
Even with clever contrast agent design, the chief limiting factor in virtually all physiologic, metabolic and molecular MR imaging and spectroscopic studies is sensitivity. This becomes particularly acute when these parameters are to be studied at high spatial resolution, as the number of signal-generating nuclei in any one voxel can become very small. This is the major reason why higher field strength magnets, despite their expense, are desirable (for spectroscopy, higher field strength also leads to better spectral separation). One area of active research is into optimal RF coil design for high-field use. While high-temperature superconducting coils have been investigated and are successfully used for spectroscopy, they have been less useful for imaging studies due to their inherently low bandwidth. Phased-array coil arrays are commonly used in clinical MRI systems at 1.5 T, but it is only recently that they have become available at 4.7 T (Beck and Blackband 2001) and continued development in this area is important to take full advantage of the signal-to-noise gains achievable at higher field strengths. Design of better volume coils should improve SNR and allow imaging of an entire animal in significantly shorter times. High-powered imaging gradients with fast switching rates for small-volume imaging have also improved the ability to acquire fast images at higher signal-to-noise, and further improvements in the gradient coils are also likely. Since targeted MR molecular imaging agents employ a range of novel contrast mechanisms, there are almost certainly opportunities to better characterize how MR image contrast changes with respect to contrast agent concentration and to improve the linearity and dynamic range of these measurements. If the image contrast can be accurately measured and/or modelled with respect to signal generation and contrast agent kinetics, then it should be possible to achieve the goal of quantifying MR molecular imaging signals over time. Finally, the cost of MR instrumentation (which is roughly 4-8 times that of a microCT scanner) remains an impediment to use outside of major core facilities, and lower cost, moderate-resolution systems with well-shielded magnets may have a role in expanding the use of the myriad of MR techniques to a somewhat wider set of users in the biomedical sciences.
Multimodality imaging
Often, it is desirable to obtain images of the same subject with multiple different imaging modalities and/or contrast agents. This is often motivated by the desire to image more than one molecular target, to correlate the timing of two signals and to add physiologic and anatomic information to molecular imaging studies. An important recent trend has therefore been the study of multimodality imaging systems in which two (or more) modalities are integrated at the instrumentation level (Hasegawa et al 2002) . Cross-modality imaging with subsequent image registration using software approaches has been studied for many years (Hill et al 2001) , and is extensively used for studies of the human brain where function as measured by PET or SPECT is accurately mapped onto the anatomy usually provided by MRI. Outside the brain, software registration techniques become more difficult to use because of organ movement and dynamic changes (for example, the bladder filling or emptying) that require sophisticated warping algorithms. Where molecular imaging studies are involved, there is often little anatomical information within the images to use to guide these image warping algorithms, further compounding the problem. However, acceptable results can be obtained when a common imaging bed or platform is used in multiple different imaging systems, and when fiducial markers are employed to aid in registration. Figure 8 shows one example of a multimodality study that was performed by registration of images acquired on two separate imaging systems. Another obvious, and ultimately more accurate solution is to develop instruments that are capable of acquiring images from multiple modalities at essentially the same time and without moving the animal.
The most common combination explored to date has been CT with either PET or SPECT (Townsend and Cherry 2001) . Combination PET/CT scanners are already in widespread use in the clinic and a small prototype for mouse imaging that enables simultaneous CT and PET images to be acquired has been recently developed (Goertzen et al 2002) . An image from this system is shown in figure 14 . Acquiring simultaneous SPECT and CT images is more challenging due to the smaller difference in the energy of the x-rays and gamma rays, however, systems capable of rapid sequential SPECT and CT imaging are being developed by a number of groups and companies (Williams et al 2000 , Iwata et al 1999 . There are also efforts to develop detectors that are sensitive both to the 511 keV photons in PET imaging and the ∼1 eV optical photons from fluorescence or bioluminescence imaging (Chatziioannou, personal communication) . If this can be achieved, it may result in instruments that are capable of both nuclear and optical imaging. Finally, there have been attempts to build small MR compatible PET systems that can be inserted into animal MRI scanners allowing PET and MRI images to be obtained simultaneously. Proof of principle data has been obtained in a range of phantom and isolated organ studies (Slates et al 1999 , Garlick et al 1997 .
It is clear that the integration of some of these modalities can lead to very powerful imaging tools that can provide information that cannot be obtained readily using two separate systems. However, the challenge is always to create an integrated system in which any compromise in image quality in either modality is avoided, or at least minimized. Furthermore, the technologies must be integrated in a user-friendly, cost effective and seamless fashion for their full complementary power to be harnessed.
Challenges in molecular imaging
The exciting new field of molecular imaging faces a number of critical challenges which it must meet in order to secure a leading role in addressing problems of health and disease in animal models and in humans. One of the major rate-limiting steps is the development of welldesigned and carefully validated contrast agents that are selective for major molecular pathways implicated in disease. Developing a high-quality contrast or diagnostic imaging agent is not dissimilar from developing a good drug, and therefore partnerships with the pharmaceutical and biotechnology industries, and some integration of drug development with the development of imaging contrast agents, are important. Attracting talented chemists and creating appropriate training programmes to increase the pool of available chemists that are interested in developing imaging agents should also be a priority. Another challenge is the transition between the many genes, many proteins environment of high-throughput screening techniques and the one gene or protein capability of most current molecular imaging technologies. Methods that allow high degrees of multiplexing of protein and/or gene imaging signals in vivo would be extremely valuable. Finally, notwithstanding the tremendous promise of these techniques, the translation of molecular imaging methodology into the clinic, and its role in the diagnosis and staging of disease, and the monitoring of therapy, is yet to be defined and demonstrated.
At the imaging system level, many challenges and opportunities remain in molecular imaging. In all modalities there is a need to improve imaging performance, either by increases in spatial or temporal resolution, sensitivity, or commonly both. The ability to accurately quantify molecular imaging studies is of great importance when these tools are used to track disease and the effects of interventions. Attempts to integrate molecular imaging studies, either with software approaches, or by building integrated instrumentation, are still relatively crude and make multi-modality studies difficult and time consuming. There are also many practical challenges associated with the efficient handling, visualization and analysis of the large volumetric datasets produced by many molecular imaging technologies. The field is young enough that there has been little attempt to standardize and cross-validate methods, data acquisition, analysis and image formats between modalities, instruments and centres. There also has been little characterization of the quantitative accuracy or reproducibility of molecular imaging methods, nor a careful statistical analysis of to what degree longitudinal molecular imaging studies provide an advantage over generally more accurate, but usually much more invasive, methods and techniques. In all these areas, and many more, there are opportunities for biomedical physicists to make significant and important contributions which will help build the solid foundation required for the future anticipated growth of molecular imaging science.
